Protocol Ledger

NCT06005610 · Phase II · TERMINATED

Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy

Interventional Phase II clinical trial protocol NCT06005610 sponsored by National Institute of Allergy and Infectious Diseases (NIAID) in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-01-04 Enrollment: 93 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06005610
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)93 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06005610
Protocol FieldVerified Registry Value
NCT IdentifierNCT06005610
Consolidated Lead SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment93 participants (ACTUAL)
Registered Start Date2024-01-04
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI